Long-Term Survival and Complete Response of a Patient with Recurrent Diffuse Intrinsic Brain Stem Glioblastoma Multiforme

Burzynski, Stanislaw R.; Lewy, Robert Ira; Weaver, Robert A.; Janicki, Tomasz; Jurida, Gabor; Khan, Mohammad Ibrahim; Larisma, Chymbeelyn B.; Paszkowiak, Jaroslaw; Szymkowski, Barbara

doi:10.1177/1534735404267748

Cited by 6 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a 4.2% rate of long survival in the brachytherapy group as compared to 0 in the other group (p=0.24; Fisher's exact test). Very long-term survival after glioblastoma treatment has been described in individual cases, [28][29][30] but this is the first study which reports a 4.2% 10-year survival in a defined group of patients treated in a specific way. However, we cannot state that the prolonged survival is due to the treatment with brachytherapy and in fact the statistical analysis suggests no relationship.…”

Section: Discussionmentioning

confidence: 94%

Coincidence vs Cause: Cure in Three Glioblastoma Patients Treated with Brachytherapy

Dehdashti

Sharma

Laperrière

et al. 2007

Can. j. neurol. sci.

View full text Add to dashboard Cite

Background:Very long term survival after diagnosis of malignant glioma has been described in individual case reports. Survival of more than 10 years is extremely rare, especially when identified in 3 out of 71 patients assigned to one arm of a randomized controlled trial.Patients:Three patients survived 11, 16, and 18 years following the diagnosis of glioblastoma and treatment with surgery, conventional fractionated radiation, and high-activity iodine-125 boost brachytherapy as part of a randomized controlled trial.Conclusion:Despite this apparent cause and effect relationship, statistical analysis shows no relationship between these cures and treatment with brachytherapy. Cure of glioblastoma remains rare.

show abstract

Section: Discussionmentioning

confidence: 94%

Coincidence vs Cause: Cure in Three Glioblastoma Patients Treated with Brachytherapy

Dehdashti

Sharma

Laperrière

et al. 2007

Can. j. neurol. sci.

View full text Add to dashboard Cite

show abstract

“…With the advent of novel chemotherapeutic drugs, improved radiation techniques (including 3-D conformation radiation, intensity modulated radiotherapy (IMRT), and stereotactic radiosurgery (SRS)), advanced surgical techniques, and a better understanding of molecular biology, the median survival could be expected to increase further in the coming years. In fact, several recent studies have reported an increased number of long term survivors [20-26]. Scoccianti et al .…”

Section: Discussionmentioning

confidence: 99%

Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis

et al. 2012

View full text Add to dashboard Cite

BackgroundGlioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors and is associated with a dismal prognosis. The median survival after the primary diagnosis remains poor, even after multimodal treatment approaches. However, a few patients have been reported to have long term survival greater than three years. A number of studies have attempted to define factors capable of predicting long term outcomes in specific patient groups. This article reports the outcomes of a very large group of patients diagnosed with GBM, and analyzes specific prognostic factors known to influence survival in these patients.MethodsWe used the Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer Institute (NCI) to investigate various patient-related and treatment- related factors that could influence the long term survival in patients diagnosed with glioblastoma. A total of 34,664 patients aged 20 years or older with a diagnosis of GBM during the years 1973 to 2008 were studied. Overall survival outcomes were examined with Kaplan-Meier survival analysis and Cox hazard models.ResultsAsian/Pacific Islanders had a better survival compared to the white population (P = <0.001). Patients diagnosed with GBM during the years 2000 to 2008 had a superior survival rate when compared with earlier decades (P = <0 .001). Statistically significant improvements in overall survival were also found for patients who received surgical resections, and adjuvant radiation treatment versus no radiation (P-values <0.001). Young age was also found to be highly predictive of improved overall survival rates when separated into age groups as well as when studied as a continuous variable.ConclusionsClinical pretreatment and treatment factors, including young age at diagnosis, Asian/Pacific Islander ethnicity, recent year of diagnosis, surgical resection and the use of adjuvant radiation therapy favorably influence survival in patients diagnosed with glioblastoma.Trial RegistrationAll data were obtained from the United States Surveillance Epidemiology and End Results (SEER) database.

show abstract

“…9 Patient 12, a 40-yearold man diagnosed with GBM of the brainstem in May 1999, underwent subtotal tumor resection and standard radiation therapy. Subsequent MRI and PET scans documented tumor recurrence.…”

Section: Case Reportmentioning

confidence: 99%

Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma

et al. 2006

Self Cite

View full text Add to dashboard Cite

Background: Brainstem glioma carries the worst prognosis of all malignancies of the brain. Most patients with brainstem glioma fail standard radiation therapy and chemotherapy and do not survive longer than 2 years. Treatment is even more challenging when an inoperable tumor is of high-grade pathology (HBSG). The objective of this report is to summarize the outcome of patients with HBSG treated with antineoplastons in 4 phase 2 trials. Patients: The following group of 18 patients was evaluable: 4 patients with glioblastomas and 14 patients with anaplastic HBSG. Fourteen patients had diffuse intrinsic tumors. Twelve patients suffered from recurrence, and 6 patients did not have radiation therapy or chemotherapy. Methods: Antineoplastons, which consist of antineoplaston A10 (A10I) and AS2-1 injections, were given in escalating doses by intravenous injections. The median duration of antineoplaston administration was 5 months, and the average dosage of A10I was 9.22 g/kg/d and of AS2-1 was 0.31 g/kg/d. Responses were assessed by gadolinium-enhanced magnetic resonance imaging and positron emission tomography. Results: The overall survival at 2 and 5 years was 39% and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma. Progression-free survival at 6 months was 39%. Complete response was achieved in 11%, partial response in 11%, stable disease in 39%, and progressive disease in 39% of patients. Antineoplastons were tolerated very well with 1 case of grade 4 toxicity (reversible anemia). Conclusion: Antineoplastons contributed to more than a 5-year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients.

show abstract

Long-Term Survival and Complete Response of a Patient with Recurrent Diffuse Intrinsic Brain Stem Glioblastoma Multiforme

Cited by 6 publications

References 10 publications

Coincidence vs Cause: Cure in Three Glioblastoma Patients Treated with Brachytherapy

Coincidence vs Cause: Cure in Three Glioblastoma Patients Treated with Brachytherapy

Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis

Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma

Contact Info

Product

Resources

About